JP2024546875A - 二連型mhc標的化t細胞エンゲージャー - Google Patents

二連型mhc標的化t細胞エンゲージャー Download PDF

Info

Publication number
JP2024546875A
JP2024546875A JP2024535534A JP2024535534A JP2024546875A JP 2024546875 A JP2024546875 A JP 2024546875A JP 2024535534 A JP2024535534 A JP 2024535534A JP 2024535534 A JP2024535534 A JP 2024535534A JP 2024546875 A JP2024546875 A JP 2024546875A
Authority
JP
Japan
Prior art keywords
pmhc
binding
antigen
domain
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546875A5 (cg-RX-API-DMAC7.html
Inventor
ボッラス,レオナルド
ユングミヒェル,シュテファニー
メルテン,ハンネス
ローベルト リヒレ,フィリップ
ベルト シャイフェレ,ファビアン
マリア ソビエライ,アンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CDR-Life AG
Original Assignee
CDR-Life AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CDR-Life AG filed Critical CDR-Life AG
Publication of JP2024546875A publication Critical patent/JP2024546875A/ja
Publication of JP2024546875A5 publication Critical patent/JP2024546875A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024535534A 2021-12-14 2022-12-13 二連型mhc標的化t細胞エンゲージャー Pending JP2024546875A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163289380P 2021-12-14 2021-12-14
US63/289,380 2021-12-14
US202263317256P 2022-03-07 2022-03-07
US63/317,256 2022-03-07
US202263328417P 2022-04-07 2022-04-07
US63/328,417 2022-04-07
PCT/EP2022/085689 WO2023110918A1 (en) 2021-12-14 2022-12-13 Dual mhc-targeting t cell engager

Publications (2)

Publication Number Publication Date
JP2024546875A true JP2024546875A (ja) 2024-12-26
JP2024546875A5 JP2024546875A5 (cg-RX-API-DMAC7.html) 2025-12-23

Family

ID=84887466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535534A Pending JP2024546875A (ja) 2021-12-14 2022-12-13 二連型mhc標的化t細胞エンゲージャー

Country Status (8)

Country Link
US (1) US20250002586A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448570A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024546875A (cg-RX-API-DMAC7.html)
KR (1) KR20240116828A (cg-RX-API-DMAC7.html)
AU (1) AU2022413444A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240046A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007473A (cg-RX-API-DMAC7.html)
WO (1) WO2023110918A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210181A1 (en) * 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
JP4902674B2 (ja) 2006-03-09 2012-03-21 エフ.ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
CA2673470A1 (en) 2006-12-21 2008-07-03 Macrogenics, Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
EP4137816B1 (en) 2014-02-11 2025-03-19 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
WO2018178307A1 (en) 2017-03-31 2018-10-04 Ablynx N.V. Improved immunogenicity assays
US20190016802A1 (en) * 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
KR20200142525A (ko) 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
KR20220015382A (ko) * 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
CA3148161A1 (en) 2019-09-05 2021-03-11 Adverum Biotechnologies Anti-drug antibody assay
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
AU2020402581A1 (en) * 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same

Also Published As

Publication number Publication date
US20250002586A1 (en) 2025-01-02
CA3240046A1 (en) 2023-06-22
KR20240116828A (ko) 2024-07-30
WO2023110918A1 (en) 2023-06-22
MX2024007473A (es) 2024-09-10
EP4448570A1 (en) 2024-10-23
AU2022413444A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
TWI718118B (zh) 針對ror1之特異性抗體及嵌合抗原受體
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
AU2018218753A1 (en) Anti-GPRC5D antibody and molecule containing same
US11912771B2 (en) MAGE-A4 peptide-MHC antigen binding proteins
CN112119099A (zh) 三特异性抗原结合蛋白
US12435444B2 (en) Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
JP7855521B2 (ja) ヒト抗cd33抗体及びその使用
US20250144141A1 (en) Mage-a4 peptide dual t cell engagers
TW202246340A (zh) 抗ctla-4抗體及其應用
US20250002586A1 (en) Dual mhc-targeting t cell engager
KR20250042908A (ko) 항-메소텔린 항체 및 이의 용도
US20250333514A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
CN118679184A (zh) 双重mhc靶向t细胞接合物
CN117751146A (zh) Mage-a4肽-mhc抗原结合蛋白
WO2025210181A1 (en) Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
TW202542204A (zh) 融合蛋白及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260804